Answers are grounded in this paper and cite their sources.
Research reveals biosynthetic pathways for d-fucofuranose and 6-deoxy-altrofuranose in Campylobacter jejuni, indicating their role in immune evasion.
Campylobacter jejuni is a Gram-negative human pathogen and is the most common cause of gastroenteritis in the United States and Europe. C. jejuni expresses a capsular polysaccharide (CPS) that enables the evasion of the host immune response and adherence to host epithelial cells. The various subspecies (serotypes) of C. jejuni are distinguished by their unique CPS repeating units. The repeating trisaccharide in the HS:41 serotype was previously found to contain l-arabinofuranose, 6-deoxy-d-altro-heptofuranose, and a third sugar, which is either d-fucofuranose or 6-deoxy-l-altrofuranose. Genome neighborhood and sequence similarity networks were employed to identify five candidate genes for the biosynthesis of d-fucofuranose and 6-deoxy-l-altrofuranose. Here, it was demonstrated that the biosynthetic pathways for both sugars are initiated by the formation of CDP-d-glucose from CTP and d-glucose-1-phosphate as catalyzed by HS41.21. This product is dehydrated by an NAD+-dependent 4,6-dehydratase (HS41.20) that produces CDP-4-keto-6-deoxy-d-glucose. The third enzyme (HS41.19) was shown to catalyze the inversion of stereochemistry at C3 and C5 using CDP-4-keto-6-deoxy-d-glucose as the substrate. The fourth enzyme (HS41.18) is an NADPH-dependent C4-reductase that catalyzes the formation of CDP-d-fucopyranose from CDP-4-keto-6-deoxy-d-glucose in the absence of the 3,5-epimerase but catalyzes the formation of CDP-6-deoxy-l-altropyranose in the presence of the epimerase. The last enzyme (HS41.17) in the pathway was shown to catalyze the FADH2-dependent interconversion of CDP-d-fucopyranose and CDP-6-deoxy-l-altropyranose to CDP-d-fucofuranose and CDP-6-deoxy-l-altrofuranose, respectively. The overall synthesis of the two possible products is governed by the catalytic activity of the epimerase, since the C4-reductase and pyranose-furanose mutase are not affected by the stereochemistry at C5.
No takes yet. Share an insight, caveat, or question.
Simons et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: